The complaint alleges a pattern of deception between October 20, 2025, and April 10, 2026. During this period, Replimune reportedly failed to disclose that its Biologics License Application (BLA) study design remained fundamentally flawed despite prior FDA warnings. Furthermore, the company allegedly presented an early, unplanned analysis of the RP1-104 trial that relied on just 40 patients—a mere fraction of the 400-person enrollment target. These omissions, the lawsuit claims, left the company’s clinical data vulnerable to rejection and rendered public statements about the firm’s operational prospects misleading.
In section Releases
Investors Scrutinize Replimune Group Following Alleged Misleading Filings
Investors who incurred significant losses in Replimune Group, Inc. are being invited to serve as lead plaintiffs in a pending class action lawsuit. The litigation, spearheaded by the Law Offices of Howard G. Smith, centers on allegations that the biotechnology firm misled stakeholders regarding critical regulatory interactions with the FDA.
Those seeking to participate as a lead plaintiff must file their intentions by October 5, 2026. While potential class members are not required to take immediate action to remain part of the collective, those interested in influencing the proceedings or reviewing their legal standing may contact the Law Offices of Howard G. Smith at 215-638-4847 or via their website.
Comments (0)
No comments yet. Be the first!